Management of Advanced Kidney Cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2013 Sep 14

PMID 24032057

Citations 5

Authors

Scott North

Naveen Basappa

Georg Bjarnason

Normand Blais

Christina Canil

Daniel Heng

Jennifer Knox

Neil Reaume

Dean Ruether

Denis Soulieres

Pawel Zalewski

Peter Black

Rodney H Breau

Rodney Breau

Michael Jewett

Anil Kapoor

Jean-Baptiste Lattouf

Ronald Moore

Ricardo Rendon

Gerald Todd

Edith Pituskin

Craig Gedye

Lori Wood

Affiliations

Soon will be listed here.

Citing Articles

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.

Canil C, Kapoor A, Basappa N, Bjarnason G, Bosse D, Dudani S Can Urol Assoc J. 2021; 15(4):84-97.

PMID: 33830005 PMC: 8021420. DOI: 10.5489/cuaj.7245.

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Hotte S, Kapoor A, Basappa N, Bjarnason G, Canil C, Conter H Can Urol Assoc J. 2019; 13(10):343-354.

PMID: 31603413 PMC: 6788909. DOI: 10.5489/cuaj.6256.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume M, Basappa N, Wood L, Kapoor A, Bjarnason G, Blais N Can Urol Assoc J. 2018; 11(10):310-320.

PMID: 29382441 PMC: 5963441. DOI: 10.5489/cuaj.4769.

Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Amdahl J, Diaz J, Park J, Nakhaipour H, Delea T Curr Oncol. 2016; 23(4):e340-54.

PMID: 27536183 PMC: 4974040. DOI: 10.3747/co.23.2244.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

North S, Basappa N, Basiuk J, Bjarnason G, Breau R, Canil C Can Urol Assoc J. 2015; 9(5-6):164-70.

PMID: 26225164 PMC: 4479636. DOI: 10.5489/cuaj.2894.

References

Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J . Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can Urol Assoc J. 2012; 6(1):16-22. PMC: 3289689. DOI: 10.5489/cuaj.11273. View

Negrier S, Perol D, Ravaud A, Chevreau C, Bay J, Delva R . Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007; 110(11):2468-77. DOI: 10.1002/cncr.23056. View

. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. Can Urol Assoc J. 2008; 2(3):175-82. PMC: 2494902. View

Choueiri T, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S . Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008; 26(1):127-31. DOI: 10.1200/JCO.2007.13.3223. View

Motzer R, Basch E . Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007; 370(9605):2071-3. DOI: 10.1016/S0140-6736(07)61874-1. View

Henry D, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J . Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29(9):1125-32. DOI: 10.1200/JCO.2010.31.3304. View

Motzer R, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O . Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013; 31(30):3791-9. PMC: 5569677. DOI: 10.1200/JCO.2012.47.4940. View

Motzer R, Escudier B, Oudard S, Hutson T, Porta C, Bracarda S . Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010; 116(18):4256-65. DOI: 10.1002/cncr.25219. View

Grunwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M . Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011; 34(6):310-4. DOI: 10.1159/000328575. View

10.

Motzer R, Bacik J, Schwartz L, Reuter V, Russo P, Marion S . Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22(3):454-63. DOI: 10.1200/JCO.2004.06.132. View

11.

. . Can Urol Assoc J. 2009; 3(3):200-204. PMC: 2692152. DOI: 10.5489/cuaj.1069. View

12.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-81. DOI: 10.1056/NEJMoa066838. View

13.

Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M . Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21(16):3150-7. DOI: 10.1200/JCO.2003.04.105. View

14.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Staehler M . Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27(20):3312-8. DOI: 10.1200/JCO.2008.19.5511. View

15.

Lipton A, Colombo-Berra A, Bukowski R, Rosen L, Zheng M, Urbanowitz G . Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004; 10(18 Pt 2):6397S-403S. DOI: 10.1158/1078-0432.CCR-040030. View

16.

Warren M, Venner P, North S, Cheng T, Venner C, Ghosh S . A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J. 2009; 3(4):281-289. PMC: 2723887. DOI: 10.5489/cuaj.1121. View

17.

Mickisch G . Urologic approaches to metastatic renal cell carcinoma. Onkologie. 2001; 24(2):122-6. DOI: 10.1159/000050298. View

18.

Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J . Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764. View

19.

Breau R, Blute M . Surgery for renal cell carcinoma metastases. Curr Opin Urol. 2010; 20(5):375-81. DOI: 10.1097/MOU.0b013e32833c7ada. View

20.

Flanigan R, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford E . Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171(3):1071-6. DOI: 10.1097/01.ju.0000110610.61545.ae. View